Overall response to immune checkpoint-inhibitors in patients with in-transit melanoma metastases
| Overall response | Total | Single-agent anti-PD-1 | Single-agent anti-CTLA-4 | Combination anti-PD-1/anti-CTLA-4 | Combination anti-PDL-1/MEK inhibitor |
| N (%) | N (%) | N (%) | N (%) | N (%) | |
| Overall | 54 (100) | 40 (100) | 8 (100) | 5 (100) | 1 (100) |
| CR | 14 (26) | 12 (30) | 1 (13) | 1 (20) | 0 |
| PR | 15 (28) | 11 (28) | 2 (25) | 1 (20) | 1 (100) |
| SD | 9 (17) | 4 (10) | 3 (38) | 2 (40) | 0 |
| PD | 16 (30) | 13 (33) | 2 (25) | 1 (20) | 0 |
CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.